# BnH-015B Clinical Trial in Moderate Alzheimer's Disease

> **NCT06535308** · PHASE1 · RECRUITING · sponsor: **BnH Research** · enrollment: 92 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** BnH-015B 5 mg
- **DRUG:** BnH-015B 10 mg
- **DRUG:** BnH-015B 20 mg
- **DRUG:** BnH-015B 40 mg (Dietary impact)
- **DRUG:** BnH-015B 40 mg
- **DRUG:** BnH-015B 80 mg
- **DRUG:** BnH-015B 160 mg
- **DRUG:** BnH-015B 40 mg (MAD)
- **DRUG:** BnH-015B 80 mg (MAD)
- **DRUG:** BnH-015B 40 mg (Part II)
- **DRUG:** BnH-015B 80 mg (Part II)
- **DRUG:** BnH-015B Placebo (Part II)

## Key facts

- **NCT ID:** NCT06535308
- **Lead sponsor:** BnH Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2026-04
- **Final completion:** 2026-06
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06535308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06535308, "BnH-015B Clinical Trial in Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06535308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*